Edition:
United Kingdom

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

2.89USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
155,968
52-wk High
$5.28
52-wk Low
$2.24

Latest Key Developments (Source: Significant Developments)

Ophthotech Q3 earnings per share $5.25
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ophthotech Corp ::Ophthotech reports third quarter 2017 financial and operating results.Q3 earnings per share $5.25.Q3 earnings per share view $2.67 -- Thomson Reuters I/B/E/S.Ophthotech Corp - ‍collaboration revenue was $206.7 million for quarter ended September 30, 2017, compared to $1.7 million for same period in 2016​.Ophthotech Corp - ‍as of September 30, 2017, company had $180.2 million in cash and cash equivalents​.Ophthotech Corp - ‍expects a 2017 year end cash balance of between $155 million and $165 million​.  Full Article

Ophthotech says Fovista phase 3 trial did not meet primary endpoint
Monday, 12 Dec 2016 

Ophthotech Corp : pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase 3 clinical trials . addition of Fovista to monthly Lucentis regimen did not result in benefit as measured by mean change in visual acuity at 12 month time point . based on preliminary analysis of safety data, Fovista and Lucentis monotherapy were generally well tolerated after one year of treatmen .Ophthotech announces results from pivotal phase 3 trials of Fovista in wet age-related macular degeneration.  Full Article

Ophthotech Q2 loss per share $0.85
Wednesday, 3 Aug 2016 

Ophthotech Corp : Q2 loss per share $0.85 . Q2 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S .Says collaboration revenue was $28.2 million for quarter ended June 30, 2016, compared to $1.6 million for same period in 2015.  Full Article

Ophthotech says achieved $30 mln enrollment milestone from Novartis Pharma
Monday, 20 Jun 2016 

Ophthotech : Says has achieved a $30 million enrollment milestone from novartis pharma ag as part of ex-us licensing . Expects to announce initial, topline data from two studies in q4 of this year . Says expects to announce initial, topline data from two studies in q4 of this year .Completes patient recruitment in phase 3 trial of Fovista® anti-pdgf therapy in combination with eylea® or avastin® in wet age-related macular degeneration.  Full Article

Ophthotech Corp announces executive changes
Tuesday, 5 Jan 2016 

Ophthotech Corp:Glenn p. sblendorio to join Ophthotech as executive vice president, chief operating officer and chief financial officer.Sblendorio succeeds michael atieh, who is retiring as executive vice president and chief financial and business officer of the company.Glenn P. Sblendorio is joining Ophthotech from medicines co, where he most recently served as president and CFO.Expects that atieh's retirement will be effective as of April 1, 2016.Sblendorio will resign as director of Ophthotech effective with assumption of new executive position,effective immediately.  Full Article

BRIEF-Ophthotech Q3 earnings per share $5.25

* Ophthotech reports third quarter 2017 financial and operating results